The Predictive Value of Endothelial Inflammatory Markers in the Onset of Schizophrenia

Gabriela Radu,1,2,* Constantin Luca,3,* Lucian Petrescu,3,* Diana Aurora Bordejevic,2,3,* Mirela Cleopatra Tomescu,1,2 Minodora Andor,1,2 Ioana Cîtu,1,2 Adelina Mavrea,1,2 Valentina Buda,4 Cătălin Tomescu,1,2 Florin Borcan,4 Liana Dehelean5 1Department of Internal Medicine I, Cardiology Cl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Radu G, Luca C, Petrescu L, Bordejevic DA, Tomescu MC, Andor M, Cîtu I, Mavrea A, Buda V, Tomescu C, Borcan F, Dehelean L
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2020
Materias:
Acceso en línea:https://doaj.org/article/d4b10cb1dc1748eebfc3dc4ca25f4f4e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:d4b10cb1dc1748eebfc3dc4ca25f4f4e
record_format dspace
institution DOAJ
collection DOAJ
language EN
topic icam-1
vcam-1
schizophrenia
inflammation
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle icam-1
vcam-1
schizophrenia
inflammation
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Radu G
Luca C
Petrescu L
Bordejevic DA
Tomescu MC
Andor M
Cîtu I
Mavrea A
Buda V
Tomescu C
Borcan F
Dehelean L
The Predictive Value of Endothelial Inflammatory Markers in the Onset of Schizophrenia
description Gabriela Radu,1,2,* Constantin Luca,3,* Lucian Petrescu,3,* Diana Aurora Bordejevic,2,3,* Mirela Cleopatra Tomescu,1,2 Minodora Andor,1,2 Ioana Cîtu,1,2 Adelina Mavrea,1,2 Valentina Buda,4 Cătălin Tomescu,1,2 Florin Borcan,4 Liana Dehelean5 1Department of Internal Medicine I, Cardiology Clinic, “Victor Babeş” University of Medicine and Pharmacy, Timişoara, Romania; 2City Emergency Hospital Timisoara, Timişoara, Romania; 3Department of Cardiology, “Victor Babeş” University of Medicine and Pharmacy, Timişoara, Romania; 4Department of Pharmacology and Clinical Pharmacy, “Victor Babeş” University of Medicine and Pharmacy, Timişoara, Romania; 5Department of Neurosciences and Psychiatry, “Victor Babeş” University of Medicine and Pharmacy, Timişoara, Romania*These authors contributed equally to this workCorrespondence: Valentina Buda 2 nd E. Murgu Square, Timişoara 300041, RomaniaTel +40755100408Email buda.valentina.oana@gmail.comPurpose: This study aimed to assess the serum levels of intracellular adhesion molecule (sICAM-1), and vascular cell adhesion molecule (sVCAM-1), in the first psychotic episode schizophrenia (SZ) patients, before and after six months of antipsychotic treatment.Patients and Methods: The study included 50 patients with a first hospitalization for SZ and 50 healthy control subjects that were patient-matched regarding age, gender, body mass index and smoking status. The evaluation included the presence of cardiovascular risk factors, measurements of systolic and diastolic blood pressure, body mass index, smoking status, ankle-brachial index, carotid intima-media thickness, and echocardiography. The Brief Psychiatric Rating Scale (BPRS) score was calculated for the patients. The plasma levels of fasting glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, sICAM-1 and sVCAM-1 were determined at baseline in all subjects and after six months of antipsychotic treatment. Thirty patients (60%) were treated with olanzapine and 20 (40%) with risperidone.Results: The average age of patients experiencing their first episode of SZ was 29.7± 6.6 years, and 23 (46%) were men. The initial sICAM-1 levels of the patients were lower than those of the control group (P< 0.0001), and increased after treatment (P=0.02), but remained lower than in the healthy controls (P=0.026). The initial levels of sVCAM-1 levels were higher in the patients (P< 0.0001) and decreased after treatment (P< 0.0001) to values that were similar to those of the control group (P=0.39). The only independent predictor of a baseline BPRS over 120 was the baseline sVCAM-1 level (P< 0.0001). Antipsychotic treatment induced significant decreases in BPRS score (P< 0.0001), in systolic (P=0.005) and diastolic (P< 0.0001) blood pressure, in HDL-c (P=0.02), as well as significant increases in blood glucose (P< 0.01) and LDL-c (P< 0.001), with no differences between olanzapine and risperidone.Conclusion: In the patients experiencing an FEP of SZ, the levels of sICAM-1 were lower, while the levels of sVCAM-1 were higher than in the healthy control subjects. The antipsychotics used in the treatment of schizophrenia increased sICAM-1 and decreased sVCAM. The baseline level of sVCAM-1 was an independent predictor of a BPRS score > 120 at baseline.Keywords: sICAM-1, sVCAM-1, schizophrenia, inflammation, atherosclerosis, cardiac dysfunction
format article
author Radu G
Luca C
Petrescu L
Bordejevic DA
Tomescu MC
Andor M
Cîtu I
Mavrea A
Buda V
Tomescu C
Borcan F
Dehelean L
author_facet Radu G
Luca C
Petrescu L
Bordejevic DA
Tomescu MC
Andor M
Cîtu I
Mavrea A
Buda V
Tomescu C
Borcan F
Dehelean L
author_sort Radu G
title The Predictive Value of Endothelial Inflammatory Markers in the Onset of Schizophrenia
title_short The Predictive Value of Endothelial Inflammatory Markers in the Onset of Schizophrenia
title_full The Predictive Value of Endothelial Inflammatory Markers in the Onset of Schizophrenia
title_fullStr The Predictive Value of Endothelial Inflammatory Markers in the Onset of Schizophrenia
title_full_unstemmed The Predictive Value of Endothelial Inflammatory Markers in the Onset of Schizophrenia
title_sort predictive value of endothelial inflammatory markers in the onset of schizophrenia
publisher Dove Medical Press
publishDate 2020
url https://doaj.org/article/d4b10cb1dc1748eebfc3dc4ca25f4f4e
work_keys_str_mv AT radug thepredictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT lucac thepredictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT petrescul thepredictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT bordejevicda thepredictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT tomescumc thepredictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT andorm thepredictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT citui thepredictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT mavreaa thepredictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT budav thepredictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT tomescuc thepredictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT borcanf thepredictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT deheleanl thepredictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT radug predictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT lucac predictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT petrescul predictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT bordejevicda predictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT tomescumc predictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT andorm predictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT citui predictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT mavreaa predictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT budav predictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT tomescuc predictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT borcanf predictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
AT deheleanl predictivevalueofendothelialinflammatorymarkersintheonsetofschizophrenia
_version_ 1718395849762930688
spelling oai:doaj.org-article:d4b10cb1dc1748eebfc3dc4ca25f4f4e2021-12-02T11:31:57ZThe Predictive Value of Endothelial Inflammatory Markers in the Onset of Schizophrenia1178-2021https://doaj.org/article/d4b10cb1dc1748eebfc3dc4ca25f4f4e2020-02-01T00:00:00Zhttps://www.dovepress.com/the-predictive-value-of-endothelial-inflammatory-markers-in-the-onset--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Gabriela Radu,1,2,* Constantin Luca,3,* Lucian Petrescu,3,* Diana Aurora Bordejevic,2,3,* Mirela Cleopatra Tomescu,1,2 Minodora Andor,1,2 Ioana Cîtu,1,2 Adelina Mavrea,1,2 Valentina Buda,4 Cătălin Tomescu,1,2 Florin Borcan,4 Liana Dehelean5 1Department of Internal Medicine I, Cardiology Clinic, “Victor Babeş” University of Medicine and Pharmacy, Timişoara, Romania; 2City Emergency Hospital Timisoara, Timişoara, Romania; 3Department of Cardiology, “Victor Babeş” University of Medicine and Pharmacy, Timişoara, Romania; 4Department of Pharmacology and Clinical Pharmacy, “Victor Babeş” University of Medicine and Pharmacy, Timişoara, Romania; 5Department of Neurosciences and Psychiatry, “Victor Babeş” University of Medicine and Pharmacy, Timişoara, Romania*These authors contributed equally to this workCorrespondence: Valentina Buda 2 nd E. Murgu Square, Timişoara 300041, RomaniaTel +40755100408Email buda.valentina.oana@gmail.comPurpose: This study aimed to assess the serum levels of intracellular adhesion molecule (sICAM-1), and vascular cell adhesion molecule (sVCAM-1), in the first psychotic episode schizophrenia (SZ) patients, before and after six months of antipsychotic treatment.Patients and Methods: The study included 50 patients with a first hospitalization for SZ and 50 healthy control subjects that were patient-matched regarding age, gender, body mass index and smoking status. The evaluation included the presence of cardiovascular risk factors, measurements of systolic and diastolic blood pressure, body mass index, smoking status, ankle-brachial index, carotid intima-media thickness, and echocardiography. The Brief Psychiatric Rating Scale (BPRS) score was calculated for the patients. The plasma levels of fasting glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, sICAM-1 and sVCAM-1 were determined at baseline in all subjects and after six months of antipsychotic treatment. Thirty patients (60%) were treated with olanzapine and 20 (40%) with risperidone.Results: The average age of patients experiencing their first episode of SZ was 29.7± 6.6 years, and 23 (46%) were men. The initial sICAM-1 levels of the patients were lower than those of the control group (P< 0.0001), and increased after treatment (P=0.02), but remained lower than in the healthy controls (P=0.026). The initial levels of sVCAM-1 levels were higher in the patients (P< 0.0001) and decreased after treatment (P< 0.0001) to values that were similar to those of the control group (P=0.39). The only independent predictor of a baseline BPRS over 120 was the baseline sVCAM-1 level (P< 0.0001). Antipsychotic treatment induced significant decreases in BPRS score (P< 0.0001), in systolic (P=0.005) and diastolic (P< 0.0001) blood pressure, in HDL-c (P=0.02), as well as significant increases in blood glucose (P< 0.01) and LDL-c (P< 0.001), with no differences between olanzapine and risperidone.Conclusion: In the patients experiencing an FEP of SZ, the levels of sICAM-1 were lower, while the levels of sVCAM-1 were higher than in the healthy control subjects. The antipsychotics used in the treatment of schizophrenia increased sICAM-1 and decreased sVCAM. The baseline level of sVCAM-1 was an independent predictor of a BPRS score > 120 at baseline.Keywords: sICAM-1, sVCAM-1, schizophrenia, inflammation, atherosclerosis, cardiac dysfunctionRadu GLuca CPetrescu LBordejevic DATomescu MCAndor MCîtu IMavrea ABuda VTomescu CBorcan FDehelean LDove Medical Pressarticleicam-1vcam-1schizophreniainflammationNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 16, Pp 545-555 (2020)